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Abstract
EU-AIMS is the largest European research program aiming to identify stratification biomarkers and novel interventions for
autism spectrum disorder (ASD). Within the program, the Longitudinal European Autism Project (LEAP) has recruited and
comprehensively phenotyped a rare sample of 76 monozygotic and dizygotic twins, discordant, or concordant for ASD
plus 30 typically developing twins. The aim of this letter is to complete previous descriptions of the LEAP case-control
sample, clinically characterize, and investigate the suitability of the sample for ASD twin-control analyses purposes and
share some ‘lessons learnt.’ Among the twins, a diagnosis of ASD is associated with increased symptom levels of ADHD,
higher rates of intellectual disability, and lower family income. For the future, we conclude that the LEAP twin cohort
offers multiple options for analyses of genetic and shared and non-shared environmental factors to generate new
hypotheses for the larger cohort of LEAP singletons, but particularly cross-validate and refine evidence from it.
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In Europe, 1 to 2% of the general population is diag-
nosed with autism spectrum disorder (ASD). ASD fre-
quently co-occurs with other neurodevelopmental and
psychiatric conditions [1, 2], persistently reduces adap-
tive functioning as well as quality of life, and is associ-
ated with premature mortality [3–5]. The genetic and
environmental interplay driving the biological trajector-
ies leading to ASD phenotypes remains poorly under-
stood, and interventions are currently not targeting
primary ASD etiologies. Althougth conceptualized as a
neurodevelopmental disorder, the diagnosis of ASD is
exclusively behavior-based, with no validated biomarkers
being available to support diagnostic assessment or
evaluate outcomes. Thus, a paramount objective of con-
temporary biomedical research on ASD is the identification
of genetic, neurobiological, and other somatic markers as
well as cognitive features that reliably characterize (sub-
groups of) autism and inform the development of novel
treatment options. In order to achieve this objective, EU-
AIMS (eu-aims.eu), the to date largest cross-disciplinary
European network of autism researchers, was established.
EU-AIMS includes the clinical research project
Longitudinal European Autism Project (LEAP) that has
collected over 700 participants with ASD or typically de-
veloping (TD) controls across a multitude of European
specialist ASD-centers. Protocol and sample details have
been previously published in this journal [6, 7]. As a sep-
arate arm within LEAP, monozygotic (MZ) and dizygotic
(DZ) twins, discordant (one twin diagnosed with ASD),
or concordant (both twins diagnosed with ASD) for
ASD plus TD control twins have been recruited. Using
largely the common LEAP-protocol, data from the LEAP
twins have been collected to enable analyses that can
disentangle genetic vs. environmental factors for any pu-
tative risk marker of ASD found within the larger LEAP
case-control cohort. Research using the twin design is
particularly informative to study potential causes of ASD,
as it provides maximum control of possible confounds,
such as sex, age, socioeconomic status, family environ-
ment, and varying genetic backgrounds [8]. The purpose
of this letter is to complete previous descriptions of the
LEAP case-control sample and protocol [6, 7] by
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providing twin sample characteristics and analyzing
options, using multiple levels of analysis.
The LEAP twin cohort includes N = 106 child, adoles-
cent, and adult twins, 96 recruited from the Roots of
Autism and ADHD Twin Study Sweden (RATSS) [9], and
10 at King’s College London (Tables 1 and 2). The LEAP
twin protocol differs from the RATSS protocol, by both
further deepening the cognitive/behavioral phenotyping
with questionnaires, psychometric tests, eye-tracking par-
adigms and structural magnetic resonance imaging (sMRI)
as well as magnet resonance spectroscopy (MRS) assess-
ments (see Additional file 1: Table S1). Clinical consensus
diagnosis of ASD, based on ICD-10, DSM-IV-TR, or
DSM-5 criteria, is supported by results from standardized
diagnostic tools, such as the Autism Diagnostic
Interview–Revised (ADI-R) [10] and the Autism Diagnos-
tic Observation Schedule-Second Edition (ADOS-2) [11,
12]. Autistic traits are measured using the parent-rated
standard form of the Social Responsiveness Scale-Second
Edition (SRS-2) [13, 14]. ADHD-symptoms are assessed
using parent and self-ratings (> 16 years of age) on the
DSM-5 ADHD rating scale. General intellectual abilities
(GAI) are measured with the Wechsler Intelligence Scales
for Children or Adults-IV (WISC-IV/WAIS-IV/WASI-II),
and intellectual disability (ID) was defined when GAI
below 70. Adaptive behavior is assessed using the parent
interview version of the Vineland Adaptive Behavior
Scales-Second Edition (VABS-2), as well as parent and
self-ratings with the Columbia Impairment Scale (CIS).
Twins without any neurodevelopmental or other disorder
were defined as TD. The twin research was approved by
the Ethical Review Boards in Stockholm and at Kings
College. Group differences on categorical variables
were calculated using chi-squared test, on rank and
continuous variables using Kruskal-Wallis test, and
Mann-Whitney test was applied as a post hoc test for
pairwise comparisons between the groups. We used
the Statistical Package for Social Sciences (IBM SPSS
version 23), and a two-tailed p < .05 was adopted for
all statistics.
The LEAP twins (38.7% female) range in age between
6 and 26 years (M = 16 years, SD = 3.85), with no age dif-
ferences between participants with or without diagnosis.
Parents with ASD twins do not differ from TD twins in
terms of education, but annual household income is
lower in these families (χ2 = 6.29; p = .043; η2 = .07),
particularly in families with ASD concordant twins (U
= 86; p = .013; η2 = .18). As expected, ASD twins show
higher autistic trait severity on the SRS-2 (χ2 = 59.10; p
< .001; η2 = .57), and autism symptom severity on the
ADI-R (total score) (χ2 = 63.88; p < .001; η2 = .63) and
ADOS (comparion scores) (χ2 = 53.10; p < .001; η2 = .53),
compared to non-ASD co-twins and TD twins.
Moreover, as expected, parent-rated adaptive behavior
levels on both the VABS and the CIS are lower in ASD
twins compared to non-ASD co-twins and TD twins.
Also, ASD twins rate themselves as more impaired on
the CIS than TD twins (U = 394; p = .033; η2 = .07), but
not compared to their non-ASD co-twins. The rate of
intellectual disability (ID) is 18.8% among ASD cases, 3.
6% in non-ASD co-twins, and 0% in TD twins (χ2 = 9.13;
p = .010; φ = .29). The groups differ on symptoms of
ADHD (χ2 = 34.75; p < .001; η2 = .37) and prescribed
ADHD medication (central stimulants, SNRIs) (χ2 = 13.
66; p = .001; φ = .38), with a medication rate of 40.4% in
ASD twins, 19.2% in non-ASD co-twins and 0% in TD
twins. If Bonferroni correction is applied, the null
hypothesis is rejected if the p < .004.
Overall, these descriptive results indicate consistency
of the twin sample with the LEAP case-control single-
tons in terms of SRS-2, ADOS-2, and ADI-R-score dis-
tributions for ASD cases [6]. Findings are also in line
with previous ASD research regarding the impact of
ASD on adaptive functioning [3, 15], and increased co-
morbidity with ADHD and ADHD symptoms. The mean
score on the ADHD rating scale-5 [16] was around the
90th percentile in ASD cases when comparing to a nor-
mative sample. Also mirroring findings from previous
research [2], other neurodevelopmental disorders and
broader phenotypes were identified in several of the
Table 1 LEAP twin sample characteristics (N = 106)
Twin-pairs concordant for ASD
n = 10
Twin-pairs discordant for ASD
n = 28
Twin-pairs with typical development
n = 15
Sex % males 80.0 62.5 46.7
Age (in years)
Mean (SD) 15.3 (3.4) 15.8 (4.4) 16.8 (2.8)
Ethnicity % Caucasian = 100 Caucasian = 88.9
Black = 3.7%
Mixed = 7.4%
Caucasian = 100
Maternal education % > high school exam 30.0 48.1 53.8
Paternal education % > high school exam 44.4 41.2 46.2
Annual household income median € 34,000–45,000 45,000–68,000 68,000–90,000
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non-ASD co-twins. Although the proportion of ASD
cases with ID appears relatively low compared to previ-
ous international research reporting an overlap of
50–70% [17], it is only slightly below more recent epi-
demiological data from Sweden (17.4–29.4%) [18]. Thus,
the risk of an overrepresentation of ASD cases without
ID in the LEAP twin sample appears limited. The inclu-
sion of twins concordant (7 MZ and 3 DZ pairs) and
discordant (10 MZ and 18 DZ pairs) for ASD, as well as
TD twins (10 MZ, 5 DZ), makes the cohort suitable for
twin co-twin approach disentangling and controlling for
genetic and environmental factors [19]. Particularly, in
including MZ twin pairs discordant for ASD, we have
the opportunity to elucidate environmental risk factors
and to test if any found association exists independent
of genetic influences. To date, only a few of studies have
applied a discordant MZ twin pair design in ASD using
smaller samples than the LEAP cohort [2, 19].
Ongoing analyses on the LEAP twins include full gen-
etic characterization of the twin pairs using a genome-
wide screen of copy number variants and whole genome
sequencing analysis. MRS data will be used to examine
the glutamate/glutamine and GABA excitation/inhib-
ition imbalance hypothesis [20]. We intend to investigate
cognitive processes, both at the level of higher con-
structs and at the more basic perceptual level, that have
been suggested to model ASD and its severity [21].
These analyses will extend recent twin findings on the
RATSS cohort, for instance, on resting state connectivity
alterations and fetal and postnatal metal dysregulation in
ASD [22, 23]. In order to fully account for the statistical
requirements of the twin/co-twin design (estimating the
between-pair or within-pair effect), and allowing for in-
clusion of both categorical and dimensional autism out-
comes, a statistical framework of multiple adjusted
(conditional) linear regressions based on generalized es-
timation equations (GEE) [24] has been developed for
the LEAP twins using the drgee package in R.
While the size of our LEAP twins sample is relatively
small, it is to the best of our knowledge the largest col-
lection of ASD twins that are comprehensively pheno-
typed and where a multitude of unique accompanying
biosamples are available. The LEAP twin sample in-
cludes a significant subset (currently about 15%) of all
ASD discordant twins in Sweden in the specified age
range [25], enabling identification of non-shared envir-
onmental influences on the phenotype [19]. As the focus
in the LEAP twin collection has been on MZ twins, the
number of included DZ pairs is rather low, making her-
itability analyses challenging. As LEAP was a RATSS
add-on, some elements from the case-control LEAP
protocol had to be excluded (e.g., functional MRI) to
minimize participant burden. A possible limitation in
twin samples is that the finding may not be generalizable
to non-twin populations. Nevertheless, as the LEAP twin
cohort shares its data collection protocol with the LEAP
case-control cohort, it is possible to cross-validate find-
ings from the LEAP case-control cohort in LEAP twins,
Table 2 LEAP twin sample diagnosis, ratings on symptoms and adaptive behavior (N = 106)
ASD twinsa
n = 48
Non-ASD twinsb
n = 28
TD twinsc
n = 30
Group comparison p value;
effect size
Between differences
(post hoc)
SRS-2d mean (SD) 90.3 (27.2) 32.9 (23.9) 30.4 (25.1) < .001; η2 = .57 a > b, c
ADI-R mean (SD)
Total score 30.4 (15.0) 7.8 (8.1) 3.8 (4.5) < .001; η2 = .63 a > b, c
ADOS-2e mean (SD) 5.9 (2.5) 1.9 (1.1) 1.9 (1.6) <.001; η2 = .53 a > b, c
Intellectual disability % 18.8 3.6 0 .010; φ = .29 a > c
Full-scale IQf mean (SD) 92.7 (19.6) 99.0 (14.6) 103.7 (13.0) .051; η2 = .06 a < c
ADHD symptomsg mean (SD) 22.9 (12.4) 11.3 (11.6) 4.2 (4.6) < .001; η2 = .37 a > b, c; b > c
VABS-2h mean (SD)
Adaptive Behavior Composite 72.8 (18.4) 95.6 (17.5) 103.2 (8.9) < .001; η2 = .41 a < b, c
CIS mean (SD)
Self reporti 9.7 (6.7) 10.3 (9.3) 6.3 (5.3) .090; η2 = .05 a > c
Parent report 14.0 (8.0) 9.3 (8.7) 6.5 (6.8) < 0.001; η2 = .17 a > b, c
Note. aIn ASD-discordant and concordant pairs
bIn ASD-discordant pairs
cTypically developed pairs
dParent-reported Social Responsiveness Scale-2
eADOS-2 comparison scores
fWISC-IV/WAIS-IV/WASI-2
gDSM-5 ADHD rating scale
hVineland Adaptive Behavior Scales-2
iColumbia Impairment Scale
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opening up the possibility to replicate singleton findings
in a twin sample, controlling for genetic factors.
Lessons learnt are the complexity of identifying and
recruiting twins even in case of excellent prerequisites
(access to national twin register), collecting complete and
usable data-sets for both twins (e.g., from sMRI, MRS)
when aiming for comprehensive phenotyping, certain
ASD subpopulations (e.g., “pure” ASD cases without
comorbidities), and clearly phenotypically ASD discordant
and concordant pairs. Given the rarity of discordant ASD
twins in countries of low population, identification and re-
cruitment must be a national, long-term, and well-funded
effort. Access to nationwide population-based registry
data on twins screened for neurodevelopmental disorders
has been invaluable. We also recommend to conduct as
many assessments online (testing, questionnaires) and
offer the opportunity to participate in more demanding
assessments (e.g., MRI, biosampling) in several regional
sites to reduce the burden of travel and time consumption,
and to take advantage of perhaps already established
contacts to clinical and research units closer to home.
Alternatively, families expressed the wish to perform the
visits during weekends, due to school and working obliga-
tions. Another lesson learnt was the apparent beneficial
effect of not only fully reimbursing the twins and their
families for travel, accommodation, loss of income, and
extra expenses, but also to pay a compensation (€200 for
RATSS, €50 for LEAP) to each twin for participation, as
well as to provide extended personal support by a research
nurse taking care of all queries and practicalities. Finally,
we also like to emphasize the importance of all partici-
pants getting annual updates on the twin research regard-
ing progress, developments, and publications.
Additional file
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twins. (DOCX 33 kb)
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